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Gadolinium (Gd)-based contrast agents (GBCAs) are used in diagnostic imaging to 
enhance the quality of magnetic resonance imaging or angiography. After intravenous 
injection, GBCAs can accumulate in the brain. Thyroid hormones (THs) are critical for the 
development and functional maintenance of the central nervous system. TH actions in 
brain are mainly exerted through nuclear TH receptors (TRs). We examined the effects 
of GBCAs on TR-mediated transcription in CV-1 cells using transient transfection-based 
reporter assay and TH-mediated cerebellar Purkinje cell morphogenesis in primary cul-
ture. We also measured the cellular accumulation and viability of Gd after representative 
GBCA treatments in cultured CV-1 cells. Both linear (Gd-diethylene triamine pentaacetic 
acid-bis methyl acid, Gd-DTPA-BMA) and macrocyclic (Gd-tetraazacyclododecane
tetraacetic acid, Gd-DOTA) GBCAs were accumulated without inducing cell death 
in CV-1 cells. By  contrast, Gd chloride (GdCl3) treatment induced approximately
100  times higher Gd accumulation and significantly reduced the number of cells. 
Low doses of Gd-DTPA-BMA (10−8 to 10−6M) augmented TR-mediated transcription, 
but the transcription was suppressed at higher dose (10−5 to 10−4M), with decreased 
β- galactosidase activity indicating cellular toxicity. TR-mediated transcription was  not 
altered by Gd-DOTA  or GdCl3, but the latter induced a significant reduction in 
β- galactosidase activity at high doses, indicating cellular toxicity. In cerebellar cultures, 
the dendrite arborization of Purkinje cells induced by 10−9M T4 was augmented by 
low-dose Gd-DTPA-BMA (10−7M) but was suppressed by higher dose (10−5M). Such 
augmentation by low-dose Gd-DTPA-BMA was not observed with 10−9M T3, probably 
because of the greater dendrite arborization by T3; however, the arborization by T3 
was suppressed by a higher dose of Gd-DTPA-BMA (10−5M) as seen in T4 treatment. 
The effect of Gd-DOTA on dendrite arborization was much weaker than that of the 
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other compounds. These results indicate that exposure to specific GBCAs may, at 
least in part, cause toxic effects in the brain by disrupting the action of THs on TRs. 
The toxic effects of GBCAs may depend on the chemical structure of GBCA and the 
dose. Thus, it is very important to choose appropriate GBCAs for imaging to prevent 
adverse side effects.
Keywords: endocrine disruption, cerebellum, neurotoxicology, development, T4, T3
learning and memory, swimming and walking abilities, and touch 
response behavior in rats (16). Thus, although controversy still 
exists, lanthanides, including Gd, may cause neurotoxic effects 
in brain. However, the mechanism that causes the toxic effects of 
lanthanides may not be fully explained by the disruption of Ca2+ 
channels and mitochondrial function.
The thyroid hormones [THs; 3,5,3′-tri-iodo-l-thyronine 
(or T3) and thyroxine (or T4)] play important roles in brain 
development, including the development of the cerebellum 
(17, 18). THs regulate various developmental processes from 
neuronal and glial proliferation to differentiation and neuronal 
migration in definitive brain regions (19). They also regulate 
the formation of neuronal cytoarchitecture and synaptogenesis 
(20). Thus, TH deficiency can change neuronal development and 
function. In addition, neuronal excitability and neurotransmitter 
transportation are also affected (21). Consequently, abnormal 
motor coordination, decreased locomotor activity, and increased 
anxiety have been observed in hypothyroid patients and experi-
mental animal models (21). It should be noted that some of these 
phenotypes may also be observed in animals that are exposed to 
Gd compounds (15, 16).
Thyroid hormone actions are mainly mediated by nuclear 
TH receptors (TRs) that bind to a specific DNA sequence, 
called TH response element (TRE), as a homodimer or a 
heterodimer with the retinoid X receptor (RXR). TRs have 
two major isoforms, such as TRα and TRβ, which are encoded 
by separate genes on human chromosomes 17 and 3, respec-
tively. Both TR isoforms are expressed in adult and developing 
brains (22). The TR–RXR complex recruits a series of cofactors 
(corepressors and coactivators) in a ligand-dependent manner 
and regulates the transcription of target genes (22–24). TH 
target genes include functional proteins that regulate various 
brain development and maintenance processes as well as 
mitochondrial functions.
Two important areas of uncertainty exist in the research 
literature. First, although several heavy metals affect TH activity 
(25, 26), the effect of Gd on TH-mediated gene expression has 
not yet been studied. Second, several brain phenotypes caused 
by Gd exposure are similar to those of hypothyroid animals; 
however, the mechanism of Gd toxicity in the brain remains 
unclear. Moreover, the effects of Gd exposure on TR-mediated 
transcription and TH-mediated brain development have not yet 
been studied.
Here, we examined the effect of Gd on TR activity and 
TH-mediated brain development in  vitro. We employed three 
different Gd compounds: Gd chloride (GdCl3) as a free Gd3+ 
source, Gd-DTPA-BMA (Omniscan™) as a linear Gd, and 
inTrODUcTiOn
Gadolinium (Gd) is a heavy metal of the lanthanide group with an 
oxidation state of +3 and an ionic radius of 0.99 Å. The trivalent 
Gd ion (Gd3+) exhibits cellular toxicity by inhibiting various 
Ca2+ channels through competitive binding with a much higher 
affinity than Ca2+ (1, 2). In spite of their toxicity, Gd-chelated 
compounds, such as chelated organic Gd complexes, have been 
used as contrast agents in magnetic resonance imaging (MRI) 
and magnetic resonance angiography. Gd-based contrast agents 
(GBCAs) are chelated forms of Gd that are manufactured to 
reduce the toxicity of Gd by avoiding the presence of free Gd3+ 
(2). GBCAs are classified as linear or macrocyclic, according 
to their chelated structure, and as ionic or non-ionic, based on 
their ion charge (1, 3). In general, compared with linear types, 
macrocyclic GBCAs are more stable, tend to bind with Gd for 
longer durations, and have lower dissociation rates (1, 2, 4).
In rodent studies, tissue deposition of Gd by GBCA exposure 
has been found in the skin, liver, kidney, lung, heart, and bones 
(5, 6). Once there, the low stability of GBCAs means that they 
may undergo transmetallation and release free Gd3+ by replace-
ment with cations, such as zinc, iron, copper, and calcium. The 
released Gd3+ is then free to attach to endogenous anions, such 
as phosphate, citrate, hydroxide, and carbonate, and can deposit 
in tissues as insoluble compounds (4, 7). In some patients 
with renal insufficiency, exposure to GBCA is known to cause 
nephrogenic systemic fibrosis (NSF) (8, 9), and although the 
exact cause remains unclear, GBCA exposure activates toll-like 
receptor (TLR) 4 and TLR7-mediated gene expression, resulting 
in increased production of many cytokines, chemokines, and 
growth factors. These include transforming growth factor beta 1 
(TGF-β1) and interleukin-6 (IL-6) in macrophages, and increase 
production of collagens I and III, fibronectin, and hyaluronic acid 
in fibroblasts (8–10). As a result of the increased production of 
these factors, tissue inflammation and fibrosis are activated and 
may cause NSF.
Gadolinium deposition has also been found in brain tis-
sue, even in patients without severe renal dysfunction (11). 
Specifically, the dentate nucleus and globus pallidus have shown 
significantly higher Gd accumulation than other brain regions (2, 
12). Moreover, Gd induces cell death by inhibiting mitochondrial 
function and by inducing oxidative stress, followed by a rapid 
accumulation of reactive oxygen in primary cultures of rat cor-
tical neurons (13, 14). By contrast, another study showed that 
administration of GBCAs does not cause any severe neurological 
alterations, such as seizures (15). On the other hand, long-term 
oral administration of other lanthanides affects functions of 
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Gd-DOTA [Dotarem™ (Magnescope™)] as a macrocyclic Gd. 
We examined the effects of these Gd compounds on cell viability 
and TR-mediated transcription using CV-1 cells. We also cultured 
newborn rat cerebellar tissue with Gd compounds to investigate 
their effect on TH-induced morphological changes in Purkinje 
cells because this is considered to be a good model for the study 
of TH action on neuronal morphogenesis and its modification by 
various chemicals and because the dendrite growth of Purkinje 
cells provides a reliable index of their function and development 
(27). Using this model, we found that Gd compounds altered 
dendritogenesis.
MaTerials anD MeThODs
chemicals
Gd chloride (GdCl3) hexahydrate (MW 371.70), with 99.9% purity 
and dissolved in distilled water, was purchased from Sigma (St. 
Louis, MO, USA) and stored in −20°C until use. Gd-DTPA-BMA 
(Omniscan™) and Gd-DOTA [Dotarem™ (Magnescope™)] 
were obtained from their respective manufacturers, and 
then diluted with distilled water to their final concentrations 
(Figure 1A). T3 (98% purity) (Sigma) was diluted using a vehicle 
(final concentration of 0.04 NaOH for 10−3M of T3 stock) as the 
diluent. T4 (98% purity), purchased from Sigma, was diluted with 
DMSO (for 10−1M of T4 stock), and then diluted with DMEM/F12 
to its final concentration from 10−1M.
Plasmids
Expression vectors for rat TRα1 and TRβ1 have previously been 
described (29, 30). The luciferase (LUC) reporter constructs, arti-
ficial direct repeat TRE, DR4 to TK-LUC (DR4-TRE), and chick 
lysozyme (F2)-thymidine kinase (TK)-LUC (F2-TRE) have also 
been described elsewhere (30).
clonal cell culture
Monkey kidney fibroblast-derived CV-1 clonal cells were main-
tained in DMEM (Sigma), supplemented with 10% fetal bovine 
serum deprived of small lipophilic hormone, with 100  U/mL 
penicillin and 100 μg/mL streptomycin (Invitrogen, San Diego, 
CA, USA) at 37°C under a 5% CO2 atmosphere. The serum was 
stripped of hormones by constant mixing with 5% (w/v) AGX1-8 
resin (Bio-Rad, Hercules, CA, USA) and powdered charcoal 
before ultrafiltration (31).
analysis of gd Deposition by inductively 
coupled Plasma-Mass spectrometry
Cells were plated at a density of 1 × 105 cells/mL in six-well plates 
until 80% confluency was achieved and were incubated in the 
presence of Gd-DTPA-BMA, Gd-DOTA, or GdCl3 for 24 h. After 
exposure, the cells were washed with phosphate buffered saline 
(PBS), and 500 μL of 0.25 w/v% Trypsin–1 mmol/L EDTA 4 Na 
solution (Wako Pure Chemical Industries, Ltd., Tokyo, Japan) 
was added before they were scraped, centrifuged at 3000 rpm for 
3 min, and washed again with PBS three times. The cell lysate was 
stored at −80°C until used for inductively coupled plasma-mass 
spectrometer (ICP-MS) measurements.
Each homogenized sample was weighed and sealed in a per-
fluoroalkoxy vial along with 0.5 mL of nitric acid and 0.1 mL of 
hydrogen peroxide (Ultrapure reagent, Kanto Chemical, Tokyo, 
Japan) for hazardous metal analysis, and it was then subjected to 
sample digestion with eight sequences of a microwave program 
for 125 min with the MLS 1200 Mega (Milestone Inc., Shelton, 
CT, USA), which is a high performance microwave digestion 
unit. After cooling, it was diluted to 10 mL with ultrapure water. 
The total concentration of Gd3+ (free + bound) in the cells was 
measured with ICP-MS (ELAN DRC II® mass spectrometer, 
Perkin Elmer Life and Analytical Sciences Inc., Waltham, MA, 
USA) with the following parameters: ICP RF (radiofrequency) 
power, 1500 W; plasma gas flow, 17.0 L/min; auxiliary gas flow, 
1.20 L/min; and nebulizer gas flow, 0.86 L/min. A standard curve 
of inorganic Gd3+ (0–300 ppm) in 3% HNO3 and digested sample 
solution was monitored by the responses of the stable isotopes 
158Gd and 160Gd. The cellular Gd concentration was determined 
by multiplying the weight of Gd per milliliter in the digested 
solution by the dilution factor and dividing it by the weight of 
the cellular sample.
cell Viability assay
We performed the 3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxy 
methoxyphenyl]-2-[4-sulfophenyl]-2Htetrazolium (MTS) cell 
proliferation assay, as described in the instruction manual of 
the Promega Technical Bulletin CellTiter 96® AQueous One 
Solution Cell Proliferation Assay. The conversion of MTS 
into aqueous soluble formazan was caused by the succinic 
dehydrogenase found in the metabolically active mitochondria. 
Cells were plated at a density of 1 × 105 cells/0.1 mL in 96-well 
plates until 80% confluency and were then incubated in the 
presence of Gd-DTPA-BMA, Gd-DOTA, or GdCl3, each for 24, 
48, and 96 h, respectively. After exposure to these compounds, 
the MTS reagent was added to the medium. The absorbance, 
representing mitochondrial metabolic activity, was measured at 
490 nm using a micro-plate reader (Bio-Rad). Relative values 
were calculated as percentages of the values obtained from the 
normal control group. All MTS studies were repeated at least 
three times in triplicate. Data are presented as means ± SEM of 
one representative experiment performed in triplicate.
Transient Transfection-Based 
reporter gene assay
Cells were plated at a density of 1 ×  105  cells/mL in 24-well 
plates until 80% confluency, and then transfected using a 
calcium–phosphate precipitation method (31). Expression vec-
tors encoding TR (0.02  μg) were cotransfected with reporter 
(F2-TRE-LUC) (0.2  μg) into CV-1 cells. Cytomegalovirus-β-
galactosidase plasmid (0.04 μg) was cotransfected as the internal 
control. At 16–18  h after transfection, cells were incubated 
with stripped medium, containing the indicated concentration 
of a vehicle (final concentration of 0.04M NaOH) or ligand 
(10−7M T3), and Gd-DTPA-BMA, Gd-DOTA, or GdCl3 for 24 h. 
Cells were then harvested to measure the luciferase activity, as 
described elsewhere (31). Total amounts of DNA (0.26 μg) per 
well were balanced by adding pcDNA3 plasmids (Invitrogen). 
FigUre 1 | chemical structures of gd-DTPa-BMa (a) and gd-DOTa (B), with gadolinium deposition shown in cV-1 cells (c,D). (a,B) molecular 
structures of Gd-DTPA-BMA and Gd-DOTA, respectively (28). The CV-1 cells were exposed to 10−8 to 10−4M of Gd-DTPA-BMA, Gd-DOTA, or GdCl3 for 24 h. The 
deposition of total gadolinium was determined by ICP-MS. Cellular Gd deposition (M/well) can be observed after Gd-DTPA-BMA and Gd-DOTA (c), and GdCl3 
treatment (D). Note that the gadolinium concentration after GdCl3 treatment was approximately 100 times higher than that after GBCA treatments. Data are 
presented as means ± SEM of experiments performed in triplicate. ***p < 0.001 and *p < 0.05 indicate statistical significance by Bonferroni’s test.
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LUC activities were normalized to β-galactosidase activity 
and then calculated as relative LUC activities. All transfection 
studies were repeated at least three times in triplicate. Data 
shown represent mean ± SEM of one representative experiment 
performed in triplicate.
Primary cerebellar culture
A pregnant Wistar rat was purchased from Japan SLC 
(Hamamatsu, Japan), and newborn rats were euthanized under 
isoflurane anesthesia on the first day of birth. The animal experi-
ment protocol in the present study was approved by the Animal 
Care and Experimentation Committee, Gunma University, and 
all efforts were made to minimize the number of animals used 
and their suffering. Details of the culture methods have been 
previously described (32). Briefly, cerebellar tissue was digested 
with 0.2  U/mL of papain (Worthington, Lakewood, NJ, USA) 
in PBS containing 0.2  mg/mL l-cysteine, 0.2  mg/mL bovine 
serum albumin (Intergen Company, Purchase, NY, USA), 5 mg/
mL glucose, and 0.02 mg/mL DNase I (Sigma, 400–600 U/mg). 
This was continued for 25 min with continued shaking at 36.5°C. 
Dissociated cells were suspended in serum-free medium without 
THs and plated at a density of 3 × 105 cells/0.3 mL in the wells 
of chamber slides (Lab-Tek 8-mm-diameter wells, Nalge Nunc 
International, Rochester, NY, USA) pre-coated with 0.1 mg/mL 
poly-l-lysine (Sigma). Then, at 16–24 h after plating, T4 (10−9M) 
or T3 (10−9M), and/or Gd-DTPA-BMA, Gd-DOTA, and GdCl3 
were added to the culture medium. One half of the medium was 
replaced with fresh medium every 3 days, and the mixed cerebel-
lar cells were cultured in a 5% CO2 incubator at 37°C for 17 days. 
The effect of dimethyl sulfoxide was excluded using control and 
experimental media at a final concentration of 0.01%, and by 
avoiding freezing and thawing.
immunocytochemistry for calbindin to 
analyze Purkinje cell Development
Immunocytochemistry of the cultured cells was performed, as 
previously described (32). Briefly, the Purkinje cells underwent 
immunochemical staining with a mouse monoclonal anti-
calbindin-28K antibody (1:200 Sigma) and a donkey anti-mouse 
IgG (H +  L) secondary antibody, Alexa Fluor® 488 conjugate 
(1:200; Thermo Fisher Scientific Inc., Waltham, MA, USA), and 
were then inspected under a laser confocal scanning microscope 
(FV1000D spectral type inverted Microscope IX81, Olympus, 
Tokyo, Japan, and ZEISS LSM 880, Carl Zeiss Microscopy GmbH, 
Jena, Germany). In some cultures, the cell nuclei were also 
stained with 4′,6-diamidino-2-phenylindole (DAPI). To quantify 
dendrite arborization, the total area covered by the dendritic 
tree on 15 randomly selected Purkinje cells per experiment was 
determined by tracing the outline of the cell and its dendritic 
branches, before computing the total area using ImageJ software 
(NIH). The numbers of Purkinje cells (calbindin-positive cells) 
and DAPI-positive nuclei per well (1  cm2) were also counted. 
Data are presented as means ± SEM, and the typical result from 
one experiment is shown graphically. More than three independ-
ent experiments were performed, and the results were consistent 
for each experiment.
statistical analysis
Treatment-related effects were analyzed using analysis of vari-
ance. Post hoc comparison was made using Bonferroni’s test. All 
p-values <0.05 were considered to be statistically significant.
resUlTs
gadolinium Deposition in cV-1 cells
Gadolinium concentration in CV-1 cells after 24 h of exposure 
was measured by ICP-MS (Figure 1B). Gd-DTPA-BMA exposure 
(10−8 to 10−4M) induced Gd accumulation in CV-1 cells, ranging 
from 3 × 10−10 to 4 × 10−7M. Although Gd-DOTA also induced 
Gd accumulation at the same dose ranges, the level of Gd depo-
sition was significantly lower than that induced by Gd-DTPA-
BMA. As a positive control, we also measured Gd deposition after 
GdCl3 treatment. In solution, Gd3+ freely dissociates from Cl−, 
and consistent with this, the levels of Gd were approximately 100 
times greater than those after GBCA treatment (Figures 1C,D). 
However, it should be noted that we observed many precipitates 
in the culture medium when the GdCl3 concentration exceeded 
10−7M. This is consistent with previous studies showing that Gd 
may be precipitated as Gd phosphate or may promote precipita-
tion of calcium–phosphate (10, 33).
effects of gBca exposure on cell Viability
The effects of Gd-DTPA-BMA, Gd-DOTA, and GdCl3 exposure 
on the viability of CV-1 cells were examined by MTS cell prolif-
eration assay. Gd-DTPA-BMA and Gd-DOTA exposure did not 
affect cell viability (Figures 2A,B). By contrast, GdCl3 reduced 
cell viability by 60% at 24 h, 29% for 48 h, and 20% at 96 h at a level 
of 10−4M (Figure 2C). These results indicate that GBCA exposure 
does not induce CV-1 cell death.
alteration of Tr-Mediated Transcription 
induced by gd-DTPa-BMa
We performed transient transfection-based reporter gene 
assay in CV-1 cells to investigate the effect of Gd-DTPA-BMA, 
Gd-DOTA, and GdCl3 on TR-mediated transcription (Figure 3). 
In the presence of T3 (10−7M), lower doses of Gd-DTPA-BMA 
(10−8 to 10−6M) augmented TRβ1-mediated transcription 
through F2-TRE, whereas transcription was suppressed by 
higher doses of Gd-DTPA-BMA (10−5 to 10−4M) (Figure  3A). 
However, exposure to Gd-DOTA did not change the TRβ1-
mediated transcription through F2-TRE in the presence of 
T3 at the same level (10−7M) (Figure 3B). Suppression of tran-
scription was also caused by high-dose GdCl3 (Figure 3C). We 
also performed similar analyses using TRα instead of TRβ and 
using DR4-TRE instead of F2-TRE. The effect was essentially 
the same, even when we changed the TR–TRE combination 
(data not shown). When we carefully examined the changes in 
β-galactosidase activities (Figures 3D–F) to evaluate the change 
in cellular function, we found that after Gd-DTPA-BMA treat-
ment, β-galactosidase activity tended to decline with increase in 
its concentration (Figure 3D). Thus, the decline in transcription 
that was observed with higher doses of Gd-DTPA-BMA may 
not be due to direct inhibition of TR-mediated transcription but 
FigUre 2 | effects of gBca or gdcl3 exposure on the cellular viability. 
CV-1 cells were exposed to several concentrations of Gd-DTPA-BMA (a), 
Gd-DOTA (B), and GdCl3 (c), each for 24, 48, and 96 h, respectively. Cell 
viability was determined by MTS assay and calculated as a percentage of the 
control viability. Data are presented as means ± SEM of experiments 
performed in triplicate. ***p < 0.001 indicates statistical significance by 
Bonferroni’s test compared with the negative control (no Gd treatment).
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rather by inhibition of cellular function. During treatment with 
GdCl3, β-galactosidase activity was significantly decreased as the 
concentration increased, indicating that Gd3+ disrupted cellular 
function (Figure  3F). In  the groups treated with Gd-DOTA, 
β-galactosidase activity was not altered (Figure 3E), regardless of 
the dose, indicating that Gd-DOTA did not affect TR-mediated 
transcription.
exposure to gd compounds impaired the 
Th-Dependent Dendrite arborization of 
Purkinje cells and induced Purkinje cell 
Death in Primary cerebellar culture
The results using CV-1 cells showed that Gd may partly dis-
rupt TH action and cause adverse effects. Consequently, we 
examined the effect of Gd-DTPA-BMA, Gd-DOTA, and GdCl3 
exposure on TH-mediated Purkinje cell development in a 
culture of newborn rat cerebellar tissue. The cerebellar cells of 
newborn pups were cultured with TH and/or Gd compounds 
for 17 days and then stained with anti-calbindin-28K antibody 
and DAPI (Figures  4 and 5). In the T4-treated cultures, the 
cells were distributed evenly in the plate (Figure  4), whereas 
in T3-treated cultures, the cells tended to aggregate in the plate 
(Figure  5). These results are consistent with previous study 
(34). Purkinje cells were located within such cellular aggregates 
in T3-treated cultures. T4 or T3 treatment markedly promoted 
the dendrite arborization of Purkinje cells. Exposure to 10−7M 
Gd-DTPA-BMA significantly augmented the 10−9M T4-induced 
arborization, whereas higher doses of Gd-DTPA-BMA (10−5M) 
dramatically inhibited it (Figure 4A). By contrast, when 10−9M 
T3 was used, Gd-DTPA-BMA (10−7M) did not augment the 
dendrite arborization (Figure 5A), probably because T3-induced 
dendrite arborization was much greater than for T4. On the 
other hand, 10−5M Gd-DTPA-BMA significantly inhibited the 
T3-induced dendrite arborization. Gd-DOTA did not affect T4-
induced dendrite arborization (Figure 4A), whereas T3-induced 
dendrite arborization was weakly suppressed by high doses of 
Gd-DOTA (Figure 5A). GdCl3 with T4 or T3 treatment mark-
edly suppressed the arborization, even at a dose of 10−7M. In 
T4-treated cultures, the number of Purkinje cells decreased with 
high doses of Gd-DTPA-BMA or any doses of GdCl3 (Figure 4C). 
In T3-treated cultures, on the other hand, treatment of all Gd 
compounds decreased the number of Purkinje cells (Figure 5C). 
The potency to decrease the number was GdCl3 > Gd-DTPA-
BMA > Gd-DOTA. Furthermore, in T4-treated cultures, 10−5M 
GdCl3 reduced the total number of cells (Figure 4D), whereas in 
T3-treated cultures, 10−5M Gd-DTPA-BMA or GdCl3 treatment 
reduced the total number of cells (Figure 5D).
DiscUssiOn
Here, we initially hypothesized that GBCAs may accumulate in 
cells and cause adverse effects by disrupting TH action in the 
brain. Consequently, we studied the effects of GBCA on cellular 
Gd concentration, TR-mediated transcription, and TH-mediated 
arborization of cultured Purkinje cell dendrites. We showed that 
Gd accumulated in CV-1 cells after GBCA and GdCl3 treatment 
for 24 h. Although TR-mediated transcription and T4-mediated 
Purkinje cell dendrite arborization were augmented by low-dose 
Gd-DTPA-BMA but suppressed by high-dose of Gd-DTPA-
BMA, Gd-DOTA at comparable levels did not alter T4-mediated 
dendrite arborization. On the other hand, T3 induced greater 
arborization than T4. Under such circumstances, the low-dose 
Gd-DTPA-BMA-induced augmentation seen with T4 was not 
detected, whereas high doses of Gd-DTPA-BMA suppressed 
FigUre 3 | effects of gBca or gdcl3 on Tr-mediated transcription. Expression plasmids encoding TRβ1 were cotransfected with F2-TK-LUC into 
CV-1 cells. Cells were cultured with or without 10−7 T3 and the indicated amount of Gd-DTPA-BMA (a,D), Gd-DOTA (B,e), or GdCl3 (c,F). To compare the 
general cellular transcriptional activity, luciferase and β-galactosidase activities in the cell lysate after Gd-DTPA-BMA (a,D), Gd-DOTA (B,e), or GdCl3 (c,F) 
treatment are shown. The total amount of DNA per well was balanced by adding a pcDNA3 vector. Data are presented as means ± SEM of experiments 
performed in triplicate. ***p < 0.001, **p < 0.01, and *p < 0.05 indicate statistical significance by Bonferroni’s test compared with TRβ1 (+), T3 (+), and 
Gd-DTPA-BMA, Gd-DOTA, or GdCl3 (−). ###p < 0.001 indicates statistical significance by Bonferroni’s test compared with TRβ1 (+), T3 (−), and Gd-DTPA-
BMA, Gd-DOTA, or GdCl3 (−).
FigUre 4 | effects of gBca or gdcl3 on the T4-induced arborization of Purkinje cell dendrites and the relative number of Purkinje cells. Cerebellar 
cells were cultured for 17 days followed by immunohistochemical analysis with calbindin and DAPI. (a) Representative photomicrographs showing the effects of 
Gd-DTPA-BMA, Gd-DOTA, or GdCl3 on Purkinje cell morphology. Bars indicate 50 μm. (B) Change in the dendritic areas of Purkinje cells following Gd-DTPA-BMA, 
Gd-DOTA, or GdCl3 treatment. (c) Change in the number of Purkinje cells/well (1 cm2) following Gd-DTPA-BMA, Gd-DOTA, or GdCl3 treatment. (D) Total number of 
DAPI-positive nuclei/well (1 cm2) following Gd-DTPA-BMA, Gd-DOTA, or GdCl3 treatment. Dendritic areas and total number of DAPI-positive nuclei were quantified 
using ImageJ software (NIH), and the total number of Purkinje and total cells/well was manually counted. Data are expressed as means ± SEM (n = 15 
determinations) and are representative of at least three independent experiments. ***p < 0.001, **p < 0.01, and *p < 0.05 indicate statistical significance by 
Bonferroni’s test compared with T4 (+), and Gd-DTPA-BMA, Gd-DOTA, or GdCl3 (−).
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FigUre 5 | effects of gBca or gdcl3 on the T3-induced arborization of Purkinje cell dendrites and the relative number of Purkinje cells. Cerebellar 
cells were cultured for 17 days followed by immunocytochemical analysis with calbindin and DAPI. (a) Representative photomicrographs showing the effects of 
Gd-DTPA-BMA, Gd-DOTA, or GdCl3 on Purkinje cell morphology. Bars indicate 50 μm. (B) Change in the dendritic areas of Purkinje cells following Gd-DTPA-BMA, 
Gd-DOTA, or GdCl3 treatment. (c) Change in the number of Purkinje cells/well (1 cm2) following Gd-DTPA-BMA, Gd-DOTA, or GdCl3 treatment. (D) Total number of 
DAPI-positive nuclei/well (1 cm2) following Gd-DTPA-BMA, Gd-DOTA, or GdCl3 treatment. Dendritic areas and total number of DAPI-positive nuclei were quantified 
using ImageJ software (NIH), and the total number of Purkinje and total cells/well was manually counted. Data are expressed as means ± SEM (n = 15 
determinations) and are representative of at least three independent experiments. ***p < 0.001, **p < 0.01, and *p < 0.05 indicate statistical significance by 
Bonferroni’s test compared with T4 (+), and Gd-DTPA-BMA, Gd-DOTA, or GdCl3 (−).
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T3-mediated Purkinje cell dendrite arborization. On the other 
hand, GdCl3 suppressed cellular function, as evidenced by 
suppressed β-galactosidase activity and its marked suppression 
of TH-mediated dendrite arborization in primary cultures. 
Furthermore, high-dose Gd-DTPA-BMA in T4-treated cultures 
and all GBCA compounds in T3-treated cultures significantly 
reduced the number of Purkinje cells. These results indicate 
that not only the Gd ion but also chelated Gd compounds may 
adversely affect the brain by disrupting TH action.
Another interesting finding of the present study is the differ-
ence of GBCA action in T4- and T3-treated cultures. As stated 
above, the cellular distribution in cultures differed between these 
two treatments in that cells were more aggregated in the T3-
treated cultures. A previous study has indicated that the reduced 
cellular migration in T3-treated cultures is due to disruption 
of integrin α3β1 and extracellular matrix interaction, which 
is activated by T4 or reverse T3, but not by T3 (34). Purkinje 
cells were usually found in the regions where the cells were 
concentrated. Dendrite arborization was augmented by both TH 
treatments. T3 showed a greater effect (1.33×) and this greater 
amount of arborization may have masked low-dose Gd-DTPA-
BMA-induced augmentation of arborization seen in T4-treated 
cultures. On the other hand, while low-dose Gd-DTPA-BMA or 
any dose of Gd-DOTA did not alter the number of Purkinje cell in 
T4-treated cultures (Figure 4C), all Gd compounds reduced the 
number of Purkinje cells in the T3-treated cultures (Figure 5C). 
The effect of Gd compounds on the total number of cells was 
also greater in the T3-treated cultures. Although the exact reason 
for this difference remains unclear, a reduction of cell-to-cell 
interaction in T3-treated cultures may have enhanced the toxicity 
of the Gd compounds.
Here, although cellular Gd accumulation was much lower 
with GBCA treatment than with GdCl3 treatment, it was 
unclear whether GBCA itself or dissociated Gd3+ was depos-
ited in the cells. A previous study demonstrated that although 
de-chelation and release of dissociated Gd3+ are observed in 
Gd-DTPA-BMA, the Gd-DOTA form is stable (35). This is 
consistent with our results, showing higher Gd accumulation 
with Gd-DTPA-BMA treatment than with Gd-DOTA treat-
ment. Thus, we assume that most of the Gd deposition in this 
study was caused by dissociated Gd3+.
After dissociation, Gd3+ may bind to anions (phosphate, 
carbonate, and hydroxide) in the body fluid to form insoluble 
salts, which may be deposited in cells where they may cause 
adverse effects (33). The results of our study support this hypoth-
esis because the level of toxicity (cell viability, β-galactosidase 
activity, and decrease in dendrite arborization) correlated 
with the magnitude of dissociation (GdCl3  >  Gd-DTPA-
BMA  >  Gd-DOTA). However, at a concentration of 10−4M, 
although Gd-DTPA-BMA and Gd-DOTA showed similar Gd 
accumulation, only Gd-DTPA-BMA suppressed TR-mediated 
transcription, decreased β-galactosidase expression, and 
decreased dendrite arborization. Additional mechanisms may 
be involved in causing such differences.
9Ariyani et al. Gadolinium-Based Agents and Thyroid Hormne
Frontiers in Endocrinology | www.frontiersin.org August 2016 | Volume 7 | Article 115
It is necessary to resolve whether dissociated Gd3+ or GBCA 
enters the cell. As mentioned earlier, dissociated Gd3+ may bind 
to anions, such as phosphate, which can then precipitate, bind 
with the plasma membrane, and disrupt cellular function, such as 
blocking calcium channels. We could not find any previous study 
showing that extracellular Gd- or Gd-chelated compounds enter 
cells by endocytosis, channels, or transporters. Here, however, 
low-dose Gd-DTPA-BMA was shown to augment TR-mediated 
transcription without altering β-galactosidase activity, as well as 
T4-activated Purkinje cell dendritogenesis. Inhibition of the activ-
ity of nuclear TR suppresses dendritogenesis in Purkinje cells, and 
this process is mediated by THs (36). These results indicate that 
Gd-DTPA-BMA suppressed TH activity in the nuclei. Although 
the mechanism causing such a disruption is unclear, several pos-
sibilities can be considered.
The first possibility is that disruption of calcium signaling 
by Gd-DTPA-BMA may alter the action of TRs. TH-mediated 
transcription is partly regulated by Ca2+/calmodulin-dependent 
protein kinase type IV (CaMKIV) (37), whose activity is triggered 
by Ca2+/calmodulin binding. Disruption of intracellular Ca2+ 
homeostasis by blocking calcium channels with Gd-DTPA-BMA 
may alter CaMKIV activity, leading to alteration of TR-mediated 
transcription. Another possibility is the disruption of membrane 
receptor-mediated TH action. In addition to nuclear TR, THs, 
particularly T4, also bind to integrin αvβ3 (38), which mediate 
various intracellular events through the protein kinase C/phos-
pholipase C pathway. Previous studies indicate that this protein 
mediates the shuttling of both TRβ and TRα from the cytoplasm 
to the nucleus (39, 40). However, Gd-DTPA can be used for inte-
grin αvβ3 imaging (41). Integrin αvβ3 is expressed in CV-1 cells 
(42) and astrocytes (43), where it mediates TH action in Purkinje 
cells by the conversion of T4 to T3. Thus, our results are consistent 
with the hypothesis that Gd-DTPA-BMA may bind to integrin 
αvβ3 and modulate TH action. However, it should be noted that 
although Gd-DTPA-BMA treatment showed a biphasic effect 
on TH activity (augmentation at low doses and suppression at 
high doses), the mechanism behind this probably depends on 
the dose, with the disruption of TR-mediated transcription at 
low doses and suppression of cellular function at higher doses. 
However, further experiments are required to clarify whether 
the disruption of TH-mediated action by Gd compounds are 
caused by disrupting the integrin αvβ3 pathway in astrocytes or 
by disrupting TR action in Purkinje cells, or both.
Gd-based contrast agents are deposited in the skin, liver, kid-
ney, lung, heart, spleen, diaphragm, and femoral muscle of rats 
(5, 6). Skin accumulation of GBCAs may cause NSF, particularly 
in patients with renal insufficiency (9, 44). This is relevant to this 
study because Gd deposition is also observed in the brain (11), 
and severe behavioral changes resulted from the administration 
of GBCA to rat brains (15). Administration of other lanthanides 
has also been associated with impaired learning and memory 
(16). Here, we also observed suppression of TH-induced den-
dritogenesis in the Purkinje cells. Together, these results indicate 
that the abnormal behavioral alteration following Gd adminis-
tration may result, at least in part, from the disruption of TH 
activity in the brain; however, further study is needed to confirm 
the mechanism. Ishitobi et al. reported that perinatal exposure 
to Cd suppressed the mRNA expression of neurogranin (RC3), 
which is a TH-regulated gene that may play an important role in 
memory and learning (45). It is possible that such alteration of 
TH-mediated gene expression may cause adverse effects.
Chelated Gd in linear or macrocyclic forms was originally 
developed to reduce the toxic effects of free Gd. GBCAs are 
used as clinically approved MRI contrast agents, and a typical 
ligand used to create a MRI contrast agent has eight donor atoms 
(1). As discussed earlier, chelated Gd has different stabilities, 
with ionic-macrocyclic Gd-DOTA being the most stable and 
non-ionic linear chelates, i.e., gadodiamide (Gd-DTPA-BMA) 
and gadoversetamide, being the least stable (7). These differ-
ent characteristics may be the reason for the different effects 
between Gd-DOTA and Gd-DTPA-BMA in the brain. Thus, 
appropriate use of GBCA is crucial to avoid adverse effects in 
the brain. Gd compounds have been found to be accumulated in 
biological and environmental samples, including surface waters 
near populated areas all over the world. GBCA application dur-
ing MRI has been shown to elevate accumulation of Gd in the 
water surface (46). This is important because we showed that 
low-dose Gd-DTPA-BMA could alter TR-mediated transcrip-
tion. Thus, more attention should be paid to environmental 
Gd pollution.
Therefore, GBCAs were deposited in CV-1 cells, but only 
Gd-DTPA-BMA altered TR-mediated transcription, with pos-
sible augmentation of TR action at low doses and inhibition of 
cellular function at high doses. Arborization of Purkinje cell 
dendrites was also altered by GBCAs in both T3- and T4-treated 
cultures. Gd-DOTA showed weak suppression of dendrite arbo-
rization at high doses and decrease in the number of Purkinje 
cells only in T3-treated cultures, in which cell-to-cell interaction 
may not be as stable as those in T4-treated cultures. Thus, this 
compound was considered to be safer compared with Gd-DTPA-
BMA. These results indicate that an appropriate GBCA should 
be used to avoid adverse effects. In addition, the possibility that 
Gd may act as an endocrine-disrupting chemical at low doses 
requires further attention.
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